Metabolic Acidosis Market is segmented By Type (Acute Metabolic Acidosis (Drug-induced Acidosis, Lactic Acidosis), Chronic Metabolic Acidosis (Renal Tubular Acidosis, Diabetic Ketoacidosis)), By Treatment (Bicarbonate Therapy (Oral Bicarbonate, Intravenous Bicarbonate), Dialysis (Hemodialysis, Peritoneal Dialysis), Pharmacological Agents (Sodium Bicarbonate Tablets, Potassium Citrate Supplements), By End User (Hospitals (Inpatient Services, Outpatient Services), Clinics (Specialty Clinics (General, Clinics), Homecare Settings (Home Dialysis, Home Medication Management)), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD million) for the above-mentioned.
Market Size in USD
CAGR5.89%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 5.89% |
Market Concentration | High |
Major Players | Tisento Therapeutics, Tricida, Advicenne Pharma, Zagociguat, Novartis |
The metabolic acidosis market is estimated to be valued at USD 177.9 Mn in 2024 and is expected to reach USD 265.5 Mn by 2031, growing at a compound annual growth rate (CAGR) of 5.89% from 2024 to 2031. The growing geriatric population who are more prone to developing metabolic acidosis due to age-related medical conditions such as kidney diseases is a major factor driving the demand.